Quarterly report pursuant to Section 13 or 15(d)

Long-Term Debt and Other Financings (Tables)

v3.20.2
Long-Term Debt and Other Financings (Tables)
9 Months Ended
Sep. 30, 2020
Long-Term Debt and Other Financings  
Aggregate Future Principal, Final Payment Fees and Discounts of Long-Term Debt

Aggregate future principal, final payment fees and discounts of the Company’s long-term debt as of September 30, 2020, are as follows (in thousands):

September 30,

2020

2020 (excluding nine months ended September 30, 2020)

$

2,270

2021

8,534

2022

21,200

Thereafter

Total payments

32,004

Less: interest, final payment fees, discount and issuance costs

(2,052)

Total payments, net of interest, final payment fees, discount and issuance costs

29,952

Less: current portion of long-term debt

(8,962)

Long-term debt

 

$

20,990

Interest Expense and Amortization of Debt Issuance Costs and Discounts

Amortization of debt issuance costs and discounts are included in interest expense. Interest expense in the condensed consolidated statements of operations and comprehensive (loss) income relates to the following debt instruments (in thousands):

Three Months Ended September 30, 

Nine Months Ended September 30, 

    

2020

    

2019

    

2020

    

2019

SVB loans

$

334

$

314

$

1,073

$

791

Novartis note

 

100

 

168

 

409

 

540

Other

 

 

2

 

2

 

5

Total interest expense

$

434

$

484

$

1,484

$

1,336